[1]吕斌,寻添荣,吴树龙,等.HPLC-MS/MS同时检测大鼠血浆中阿托伐他汀和伏立康唑的浓度[J].南方医科大学学报,2019,(03):337.
点击复制

HPLC-MS/MS同时检测大鼠血浆中阿托伐他汀和伏立康唑的浓度()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2019年03期
页码:
337
栏目:
出版日期:
2019-04-11

文章信息/Info

Title:
Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study
作者:
吕斌寻添荣吴树龙占霞荣艳张庆杨西晓
关键词:
阿托伐他汀伏立康唑HPLC-MS/MS药代动力学相互作用
Keywords:
atorvastatin voriconazole high-performance liquid chromatography-tandem mass spectrometry pharmacokinetics interaction
摘要:
目的建立并应用同时测定大鼠血浆中阿托伐他汀和伏立康唑浓度的液相质谱联用方法(HPLC-MS/MS),研究阿托伐他 汀单独给药及与伏立康唑联合给药后,大鼠体内阿托伐他汀的药动学变化以及伏立康唑的浓度变化。方法采用醋酸钠酸化, 甲基叔丁基醚液-液萃取法处理血浆样品,经Thermo Hypersil Gold C1(8 2.1×100 mm, 1.9 μm)色谱柱分离,流动相为乙腈-0.1%甲 酸水溶液,梯度洗脱,分析时间6 min;质谱检测采用加热电喷雾离子源(H-ESI)正离子扫描方式,选择反应监测(SRM)模式检 测,选用m/z559.2→440.2(阿托伐他汀)、m/z350.2→281(伏立康唑)、m/z370.2→252(内标兰索拉唑)作为定量分析的离子。结 果阿托伐他汀在0.01~100 ng/mL(r=0.9957),伏立康唑在0.025~100 ng/mL(r=0.9966)范围内线性关系良好,阿托伐他汀和伏 立康唑的日间和日内精密度均小于13%,提取回收率66.50%~82.67%,血浆样品稳定性符合测定要求。单独给药和联合给药后 大鼠血浆中阿托伐他汀的AUC0-24 h分别为(438.78±139.61)和(927.43±204.12))h·μg·L-1,CLz/F分别为(23.89±8.14)和(10.43± 2.58)L·h-1·kg-1,Cmax分别为(149.62±131.10)和(159.37±36.83)μg·L-1,t1/2分别为(5.08±1.63)和(5.58±2.11)h,Tmax分别为(0.37± 0.14)和(3.60±1.52)h,其中AUC0-24 h和CLz/F,Tmax具有显着性差异(P<0.05)。同时可测定合并给药组中伏立康唑的血药浓度。 结论本方法简单快速,灵敏度高,可用于同时检测大鼠血浆中阿托伐他汀和伏立康唑的浓度。伏立康唑和阿托伐他汀联用,使 阿托伐他汀的部分药代动力学参数发生了改变。
Abstract:
Objective To develop a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for simultaneous determination of atorvastatin and voriconazole in rat plasma and investigate the pharmacokinetics of atorvastatin and the changes in voriconazole concentration in rats after administration. Methods Plasma samples were collected from rats after intragastric administration of atorvastatin alone or in combination with voriconazole. The samples were treated with sodium acetate acidification, and atorvastatin and voriconazole in the plasma were extracted using a liquidliquid extraction method with methyl tert-butyl ether as the extractant. The extracts were then separated on a Thermo Hypersil Gold C18 (2.1×100 mm, 1.9 μm) column within 6 min with gradient elution using acetonitrile and water (containing 0.1% formic acid) as the mobile phase; mass spectrometry detection was achieved in selective reaction monitoring (SRM) mode under the positive ion scanning mode of heated electrospray ion source (H-ESI) and using transition mass of m/z 559.2→440.2 for atorvastatin and m/z 350→280 for voriconazole, with m/z370.2→252 for lansoprazole (the internal standard) as the quantitative ion. Results The calibration curves were linear within the concentration range of 0.01-100 ng/mL (r=0.9957) for atorvastatin and 0.025-100 ng/mL (r=0.9966) for voriconazole. The intra-day and inter-day precisions were all less than 13%, and the recovery was between 66.50% and 82.67% ; the stability of the plasma samples met the requirements of testing. The AUC0-24 h of atorvastatin in rat plasma after single and combined administration was 438.78±139.61 and 927.43±204.12 h·μg·L-1, CLz/F was 23.89±8.14 and 10.43±2.58 L·h-1 ·kg-1, Cmax was 149.62±131.10 and 159.37±36.83 μg/L, t1/2 was 5.08±1.63 and (5.58±2.11 h, and Tmax was 0.37 ± 0.14 and 3.60 ± 1.52 h, respectively; AUC0- 24 h, CLZ/F and Tmax of atorvastatin in rat plasma differed significantly between single and combined administration. The HPLC-MS/MS system also allowed simultaneous determination of voriconazole concentration in rat plasma after combined administration. Conclusion The HPLC-MS/MS system we established in this study is simple, rapid and sensitive and allows simultaneous determination of atorvastatin and voriconazole in rat plasma. Some pharmacokinetic parameters of atorvastatin are changed in the presence of voriconazole , and their clinical significance needs further investigation.

相似文献/References:

[1]邓明尧,吴国平,冯旭霞,等.不同剂量阿托伐他汀对不稳定性心绞痛患者的临床疗效及其血清血管内皮生长因子表达的比较[J].南方医科大学学报,2011,(09):1635.
[2]宋元彬,丘若峰,邝健,等.阿托伐他汀对大鼠急性心肌梗死后心功能及TGF-β1信号通路的影响[J].南方医科大学学报,2012,(02):202.
[3]张今尧,王浩,叶平.阿托伐他汀对老年大鼠心肌缺血再灌注损伤及多器官功能的保护作用[J].南方医科大学学报,2012,(03):322.
[4]宋杰丽,曾锦培,张永霞,等.复方丹参滴丸联合阿托伐他汀对经皮冠状动脉腔内血管成形术后内膜增生的影响[J].南方医科大学学报,2014,(09):1337.
[5]曹世平,王鹏,崔凯,等.阿托伐他汀通过抑制氧化应激预防对比剂肾病[J].南方医科大学学报,2012,(11):1600.
[6]张今尧,王浩,叶平.阿托伐他汀对老年大鼠多器官内皮型一氧化氮合酶的影响及其在心肌缺血再灌注中的作用[J].南方医科大学学报,2012,(12):1708.
[7]童保文,林志鸿,谢良地,等.兔颈动脉球囊损伤后血小板聚集和活化及阿托伐他汀的作用[J].南方医科大学学报,2014,(08):1162.
[8]高菊华,高小平,潘速跃.阿托伐他汀强化治疗可减少大脑中动脉支架置入后脑血管事件的发生[J].南方医科大学学报,2016,(03):356.

更新日期/Last Update: 1900-01-01